Key Highlights:
- HRV Pharma has signed definitive agreements to acquire 100% of Germany-based Phatebo GmbH from ZeroStack Corp., marking its entry into finished formulations and expanding its pharmaceutical operations beyond active pharmaceutical ingredients (APIs).
- Founded in 2015, Phatebo generated approximately ₹350 crore in 2025 revenue and specializes in clinical trial supply, sourcing comparator, investigational and ancillary medicines for global pharmaceutical companies and contract research organizations.
- The acquisition adds a licensed German pharmaceutical business, established distribution systems and global sponsor relationships to HRV’s network of 50+ certified manufacturing partners and customers across 55 countries. Phatebo will retain its name, team and Hilzingen operations.
Implications:
The acquisition marks a strategic shift for HRV Pharma from API-focused operations into finished formulations and clinical trial supply, diversifying its revenue streams. Phatebo’s established German licensing, distribution infrastructure and global pharmaceutical relationships could strengthen HRV’s access to European markets and expand its contract services portfolio. The deal also positions HRV to capture growing demand for outsourced clinical trial supply while creating opportunities to integrate its manufacturing partner network with Phatebo’s sourcing and distribution capabilities.
Source: Express Pharma
